802 related articles for article (PubMed ID: 26272769)
1. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
Rapoport BL; Chasen MR; Gridelli C; Urban L; Modiano MR; Schnadig ID; Poma A; Arora S; Kansra V; Schwartzberg LS; Navari RM
Lancet Oncol; 2015 Sep; 16(9):1079-1089. PubMed ID: 26272769
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Schwartzberg LS; Modiano MR; Rapoport BL; Chasen MR; Gridelli C; Urban L; Poma A; Arora S; Navari RM; Schnadig ID
Lancet Oncol; 2015 Sep; 16(9):1071-1078. PubMed ID: 26272768
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
4. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
6. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.
Kang HJ; Loftus S; Taylor A; DiCristina C; Green S; Zwaan CM
Lancet Oncol; 2015 Apr; 16(4):385-94. PubMed ID: 25770814
[TBL] [Abstract][Full Text] [Related]
7. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Ruhlmann CH; Christensen TB; Dohn LH; Paludan M; Rønnengart E; Halekoh U; Hilpert F; Feyer P; Kristensen G; Hansen O; Keefe D; Herrstedt J
Lancet Oncol; 2016 Apr; 17(4):509-518. PubMed ID: 26952945
[TBL] [Abstract][Full Text] [Related]
9. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
10. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
Support Care Cancer; 2017 Jan; 25(1):85-92. PubMed ID: 27557833
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
Hesketh PJ; Schnadig ID; Schwartzberg LS; Modiano MR; Jordan K; Arora S; Powers D; Aapro M
Cancer; 2016 Aug; 122(15):2418-25. PubMed ID: 27176138
[TBL] [Abstract][Full Text] [Related]
12. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Kovács G; Wachtel AE; Basharova EV; Spinelli T; Nicolas P; Kabickova E
Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
14. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
15. Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting.
Rapoport BL
Rev Recent Clin Trials; 2017; 12(3):193-201. PubMed ID: 28393710
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.
Suzuki K; Yamanaka T; Hashimoto H; Shimada Y; Arata K; Matsui R; Goto K; Takiguchi T; Ohyanagi F; Kogure Y; Nogami N; Nakao M; Takeda K; Azuma K; Nagase S; Hayashi T; Fujiwara K; Shimada T; Seki N; Yamamoto N
Ann Oncol; 2016 Aug; 27(8):1601-6. PubMed ID: 27358385
[TBL] [Abstract][Full Text] [Related]
17. Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV).
Rashad N; Abdel-Rahman O
Drug Des Devel Ther; 2017; 11():947-954. PubMed ID: 28392676
[TBL] [Abstract][Full Text] [Related]
18. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
19. Rolapitant: A Review in Chemotherapy-Induced Nausea and Vomiting.
Heo YA; Deeks ED
Drugs; 2017 Oct; 77(15):1687-1694. PubMed ID: 28929404
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]